ArticleFrontiers in neurology2026
Endovascular treatment of congenital arteriovenous fistulas in the parotid region using coils and absolute ethanol.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical features and therapeutic outcomes of endovascular embolization for congenital arteriovenous fistulas (cAVFs) located in the parotid region. Methods: Fifteen consecutive patients with parotid cAVFs who underwent endovascular embolization between September 2017 and September 2025 were retrospectively reviewed. The cohort comprised nine males and six females, including six children (median age: 4 years) and nine adults (median age: 35 years). Clinical presentations, computed tomography imaging, and digital subtraction angiography data were analyzed. The therapeutic protocol involved primary coil embolization of the dilated draining vein to achieve flow reduction, followed by the targeted administration of absolute ethanol to obliterate the residual shunt. Results: The predominant clinical manifestations were pulsation (14/15, 93.3%), followed by thrill (7/15, 46.7%), elevated skin temperature (7/15, 46.7%), tinnitus (3/15, 20%), and hemorrhage (1/15, 6.7%). All patients were managed via combined embolization using detachable coils (median: 7), fibered coils (median: 21), and absolute ethanol (median: 10 mL). The complete response rate was 86.7% (13/15) at the 3-month and 6-month follow-ups after the initial treatment. At the 1-year follow-up, the final complete symptom resolution rate reached 100% (15/15) after repeat sessions in selected cases. Complications included transient localized swelling (15/15, 100%), temporary facial nerve paralysis (1/15, 6.7%), and late coil exposure via the external auditory canal (1/15, 6.7%), all of which resolved with targeted management. Conclusion: Endovascular embolization using a combination of coils and absolute ethanol is a clinically viable and effective strategy for the management of parotid cAVFs. While localized swelling is a universal post-procedural event, major systemic complications are rare, rendering this technique a valuable minimally invasive alternative to open surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.